Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company

We are focused on developing novel, transformative medicines for neurological diseases, with an initial focus on rare diseases.

Our Story

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, with an initial focus on rare diseases.

Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. to advance a portfolio of centrally-acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). GPCRs have been proven to be the most successful class of druggable targets in the human genome and make up 50-60% of all druggable targets in the body. Longboard’s small molecule product candidates were discovered out of the same world-class GPCR research platform at Arena that represents a culmination of more than 20 years of drug development and optimization.

Longboard is evaluating LP352, an oral, centrally acting, next-generation 5-hydroxytryptamine 2C

Longboard is evaluating LP352, an oral, centrally acting, next-generation 5-hydroxytryptamine 2c (5-HT2c) receptor superagonist, with negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes, in development for the potential treatment of seizures associated with developmental and epileptic encephalopathies (DEEs). DEEs refer to a group of severe heterogeneous epilepsies characterized by drug resistant seizures and significant developmental delay.

.

(5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes. LP352 is in development for the potential treatment of seizures associated with developmental and epileptic encephalopathies (DEEs). DEEs refer to a group of severe heterogeneous epilepsies that are characterized by drug resistant seizures and significant developmental delay.

Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.

Management

Kevin Lind

President and CEO

Randall Kaye, M.D.

Chief Medical Officer

Brandi Roberts

Chief Financial Officer

Steven Spector

General Counsel

Gus Cardenas

Vice President and Head of Quality Assurance

Anne Danks, Ph.D.

Vice President and Head of Preclinical Development

Dewey McLin, Ph.D.

Vice President and Head of Medical Affairs

Chad Orevillo

Vice President and Head of Operations

Jodi Parsons, Ph.D.

Vice President and Head of Regulatory Affairs

Marco Peters, Ph.D.

Vice President and Head of Translational Science

Board of Directors


Kevin Lind

President and CEO


Vincent Aurentz

Board Member


Casey Lynch

Board Member


Phillip Schneider

Board Member


Paul Sekhri

Board Member